Cap Biotechnology: Expected net loss of 1.2 billion to 1.95 billion in 2025.

Capp Biotech announced that the net profit attributable to shareholders of the listed company is expected to be between -195 million yuan and -120 million yuan in 2025, compared to -655 million yuan in the same period last year, an increase of 70.22% - 81.68%. The non-recurring net profit is expected to be between -218 million yuan and -143 million yuan, compared to -660 million yuan in the same period last year, an increase of 66.96% - 78.32%. The performance change is mainly due to the centralized procurement of HPV - DNA testing series products, adjustment of value-added tax rate, decrease in revenue from testing services, operating losses in new hospitals, and impairment of assets. This performance forecast has not been audited, and specific data will be disclosed in the annual report.